mojeNovosti.com
Under the terms of the deal, Janssen will fully fund the research to be done at Genmab, and Genmab will potentially be entitled to milestone and license payments of up to about $175 million for each product as well as royalties on any commercialized products, Genmab said late on Thursday.
The deal with Janssen followed a collaboration agreement with Novartis in June to use Genmab's DuoBody technology.
The DuoBody platform, introduced in 2010 is a technology for the discovery and development of antibodies that may improve antibody therapy of cancer, autoimmune, infectious and central nervous system disease, Genmab said in the statement.
(Reporting by John Acher; Editing by Eric Meijer)
Copyright 2013 mojeNovosti.com
web developer: BTGcms
